Newsroom | 463926 results
Sorted by: Latest
-
5 Stones intelligence (5Si)® Launches The Art of Intelligence™ Thought Leadership Platform
MIAMI--(BUSINESS WIRE)--5Si® launches The Art of Intelligence™ cinematic thought leadership platform exploring modern intelligence, risk, and high-stakes decision-making....
-
Render Networks Advances ClearWay with Field Quality Agent, Bringing Real-Time Validation to Critical Infrastructure Execution
DENVER--(BUSINESS WIRE)--Render Networks Advances ClearWay with Field Quality Agent, Bringing Real-Time Validation to Critical Infrastructure Execution...
-
Ameresco's Kūpono Project Named Winner in 2026 Environment+Energy Leader Awards
FRAMINGHAM, Mass.--(BUSINESS WIRE)--Ameresco's Kūpono Project Named Winner in 2026 Environment+Energy Leader Awards...
-
SmartBear Delivers New ReadyAPI AI Test Generation Capability to Accelerate API Test Creation and Enhance Application Integrity
SOMERVILLE, Mass.--(BUSINESS WIRE)--SmartBear, helping teams build, test, and ship quality software at AI speed and scale, today announced ReadyAPI’s new AI test generation capability that accelerates API testing by up to 80%1 while giving teams complete control to enable or disable AI based on where they are in their AI journeys. While competitors focus on speed alone, ReadyAPI’s AI test generation capability is architected for quality at scale and addresses the testing gap by aligning validat...
-
Spotify Technology S.A. to Host Investor Day 2026
NEW YORK--(BUSINESS WIRE)--As previously announced, Spotify Technology S.A. (NYSE: SPOT) will host an Investor Day in New York City on Thursday, May 21, 2026 beginning at 10:00 a.m. Eastern Time (ET). Hear from Spotify’s Co-Chief Executive Officers, Alex Norström and Gustav Söderström, Chief Financial Officer, Christian Luiga, and members of our leadership team as they lay out our long-term vision and strategic priorities. A live Q&A will follow the main presentation. A live webcast of Spot...
-
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
ALAMEDA, Calif.--(BUSINESS WIRE)--Scribe Therapeutics reports preclinical data at ASGCT 2026 demonstrating enhanced potency and specificity of engineered CRISPR technologies...
-
New Survey from LegalZoom Reports Entrepreneurs Use AI to Move Faster, But Turn to Human Guidance When Risk is Real
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--LegalZoom (Nasdaq: LZ), America’s #1 online legal services company, today released findings from a comprehensive survey of 1,000 respondents — 500 aspiring founders and 500 current business owners — across the United States. The survey examined AI adoption rates, how and when founders rely on AI tools, the perceived value it provides, and what concerns remain. The results paint a picture of a business community that is rapidly embracing AI, with both enth...
-
Fiber Broadband Association Publishes Paper on Transitioning Cable Networks to Fiber-to-the-Home
ORLANDO, Fla.--(BUSINESS WIRE)--Today at Fiber Connect 2026, the Fiber Broadband Association (FBA) published a new technical paper, Upgrading MSO Networks to Fiber to the Home (FTTH): A Technical Perspective, outlining strategies for cable operators to transition from legacy hybrid fiber coaxial (HFC) networks to fiber-to-the-home (FTTH) infrastructure. FBA’s Technology Committee developed the paper, examining deployment models, technology options, and operational considerations for Multiple Sy...
-
HistoSonics erhält bahnbrechende TFDA-Zulassung in Taiwan und beschleunigt damit globale Expansion
MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics, der Entwickler des Edison® Histotripsy-Systems und der neuartigen Histotripsie-Therapieplattform, gab heute bekannt, dass das Unternehmen die Zulassung seitens der Taiwan Food and Drug Administration (TFDA) für das Edison® System erhalten hat. Dies ist ein bedeutender Meilenstein in den globalen Expansionsbemühungen des Unternehmens und seines Wachstumskurses in Asien. Dank seiner strengen regulatorischen Standards und seiner äußerst innovativen Ärzteg...
-
HistoSonics加速全球扩张,在台湾地区获得具有里程碑意义的TFDA批准
明尼阿波利斯--(BUSINESS WIRE)--(美国商业资讯)-- Edison®组织碎化系统及新型组织碎化治疗平台的开发商HistoSonics今日宣布,其Edison®系统已获得台湾食品药物管理局(TFDA)的批准,这标志着该公司在全球扩张及亚洲地区持续发展进程中迈出了重要一步。 台湾地区被公认为亚洲最先进且具有重要战略意义的医疗器械市场,以严格的监管标准和极具创新精神的医生群体而闻名。台湾食品药物管理局(TFDA)的审批流程包括详细审查公司提交的临床和监管资料包,并最终获得委员会成员一致批准。 此次批准进一步巩固了组织碎化术日益增强的临床和监管势头。该技术是一种非侵入性、非热效应的聚焦超声技术,旨在通过机械作用将目标组织和肿瘤液化并破坏,无需手术或放疗。 HistoSonics董事长兼首席执行官Mike Blue表示,“此次获批是HistoSonics的重要里程碑,也标志着组织碎化术在亚洲的推广取得重大进展。获得台湾食品药物管理局(TFDA)的批准,充分证明了我们临床证据的可靠性、监管工作的严谨性,以及业界对组织碎化技术作为一种变革性无创治疗平台的信心日益增强。” Histo...